Evommune (EVMN) Liabilities and Shareholders Equity (2024 - 2026)
Evommune (EVMN) posted quarterly Liabilities and Shareholders Equity of $322.5 million for Q1 2026, up 43.35% quarter-over-quarter from $224.9 million in Q4 2025.
Evommune (EVMN) Liabilities and Shareholders Equity (2024 - 2026) Analysis & Trends
Evommune (EVMN) has reported Liabilities and Shareholders Equity for 3 consecutive years, with $322.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity changed N/A year-over-year to $322.5 million; the TTM figure through Mar 2026 stood at $631.9 million (changed N/A YoY), while the FY2025 annual figure was $224.9 million, up 195.77% from the prior year.
- Liabilities and Shareholders Equity grew to $322.5 million in Q1 2026 per EVMN's latest filing, from $224.9 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $322.5 million in Q1 2026 and bottomed at $76.1 million in Q4 2024.
- Historically, Liabilities and Shareholders Equity has averaged $177.0 million across 3 years, with a median of $154.7 million in 2025.
- On a YoY basis, Liabilities and Shareholders Equity climbed as much as 195.77% in 2025 and fell as far as 195.77% in 2025.
- Evommune's Liabilities and Shareholders Equity stood at $76.1 million in 2024, then jumped by 195.77% to $224.9 million in 2025, then soared by 43.35% to $322.5 million in 2026.
- Business Quant data shows EVMN's Liabilities and Shareholders Equity at $322.5 million in Q1 2026, $224.9 million in Q4 2025, and $84.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Evommune | 531.53 Mn | 330.73 Mn | - | 301.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 301.95 Mn |
| Mar 31, 2026 | 322.46 Mn |
| Dec 31, 2025 | 224.95 Mn |
| Sep 30, 2025 | 84.54 Mn |
| Dec 31, 2024 | 76.06 Mn |